Literature DB >> 7009108

Pathogenesis of atherosclerosis in diabetes mellitus.

J A Colwell, M Lopes-Virella, P V Halushka.   

Abstract

Numerous studies have shown that patients with diabetes mellitus have accelerated atherosclerotic vascular disease, and major advances in understanding it pathogenesis have been made. Current suggestions are that endothelial injury may be the initial event in the genesis of atherosclerosis, followed by platelet adhesion and aggregation at the site of injury. In diabetes, evidence of endothelial dysfunction is present. Smooth muscle cell proliferation is an important pathologic finding in atherosclerosis. This process is stimulated by a platelet mitogen, which has been partially characterized. The mitogen has not been studied in diabetes. Lipid accumulation in the area of the atherosclerotic lesion is primarily in the form of intracellular and extracellular esterified cholesterol. In uncontrolled diabetes, elevated plasma low density lipoprotein levels and decreased plasma high density lipoprotein levels favor lipid deposition in large vessels. There is evidence of a thrombotic state in certain diabetic patients. Collectively, these abnormalities of endothelial, platelet, smooth muscle, lipoprotein, and coagulation behavior may be viewed as contributing to the problem of accelerated atherosclerosis in diabetes. A thorough understanding of the pathogenesis of this process aids in designing appropriate preventive therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7009108     DOI: 10.2337/diacare.4.1.121

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  21 in total

1.  Marine lipids normalize cholesteryl ester transfer in IDDM.

Authors:  J D Bagdade; M Ritter; P V Subbaiah
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

Review 2.  Concise Review: Macrophages: Versatile Gatekeepers During Pancreatic β-Cell Development, Injury, and Regeneration.

Authors:  Naomi Van Gassen; Willem Staels; Eva Van Overmeire; Sofie De Groef; Mozhdeh Sojoodi; Yves Heremans; Gunter Leuckx; Mark Van de Casteele; Jo A Van Ginderachter; Harry Heimberg; Nico De Leu
Journal:  Stem Cells Transl Med       Date:  2015-04-06       Impact factor: 6.940

3.  Immunopathology of desialylation: human plasma lipoprotein(a) and circulating anti-carbohydrate antibodies form immune complexes that recognize host cells.

Authors:  P S Sabarinath; P S Appukuttan
Journal:  Mol Cell Biochem       Date:  2015-01-30       Impact factor: 3.396

Review 4.  Antiplatelet agents and diabetic vascular disease.

Authors:  J A Colwell
Journal:  Trans Am Clin Climatol Assoc       Date:  1987

5.  The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.

Authors:  Arwa Younis; Dana Eskenazi; Ronen Goldkorn; Jonathan Leor; Nili Naftali-Shani; Enrique Z Fisman; Alexander Tenenbaum; Ilan Goldenberg; Robert Klempfner
Journal:  Cardiovasc Diabetol       Date:  2017-05-22       Impact factor: 9.951

6.  Platelet aggregation after strict metabolic control using the artificial pancreas.

Authors:  D Giugliano; L Misso; A Tirelli; L Coppola; P Di Pinto; R Torella
Journal:  Diabetologia       Date:  1982-12       Impact factor: 10.122

Review 7.  Pharmacokinetic optimisation of oral hypoglycaemic therapy.

Authors:  P Marchetti; R Giannarelli; A di Carlo; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

8.  Lack of a persistent reduction in serum lipid and apoprotein levels in insulin-dependent diabetic patients receiving intensified insulin treatment.

Authors:  R B Goldberg; M L Reeves; D E Seigler; E A Ryan; N Miller; S L Hsia; J S Skyler
Journal:  Acta Diabetol Lat       Date:  1985 Apr-Jun

9.  Percutaneous transluminal angioplasty in diabetic patients: an effective treatment modality.

Authors:  K Ford; S D Braun; A V Moore; G A Miller; N R Dunnick
Journal:  Cardiovasc Intervent Radiol       Date:  1984       Impact factor: 2.740

10.  1,25(OH)2D3 inhibits oxidative stress and monocyte adhesion by mediating the upregulation of GCLC and GSH in endothelial cells treated with acetoacetate (ketosis).

Authors:  Preeti Kanikarla-Marie; Sushil K Jain
Journal:  J Steroid Biochem Mol Biol       Date:  2016-03-03       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.